By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aeglea BioTherapeutics 

901 S. MoPac Expressway
Barton Oaks Plaza One
Suite 250

Austin  Texas  78746  U.S.A.
Phone: 512-942-2935 Fax: 512-872-5121


Key Statistics

Ownership: Private

Web Site: Aeglea


Company News
Top 20 Life Science Startups to Watch in the U.S. 1/26/2016 7:46:23 AM
Aeglea Announces FDA Acceptance Of Its Investigational New Drug Application For AEB1102 For The Treatment Of Arginase I Deficiency 1/7/2016 11:02:21 AM
What You Need to Know About Aeglea 12/2/2015 1:46:24 PM
Aeglea Doses First Patient In Phase I Study Of AEB1102 For Treatment Of Solid Tumors 10/26/2015 7:43:59 AM
Aeglea Announces Promotion Of Charles N. York To Chief Financial Officer 9/28/2015 12:45:00 PM
Aeglea Announces Publication Of Nonclinical Data On Lead Molecule, AEB1102, In Human Molecular Genetics 9/16/2015 11:53:45 AM
Aeglea Announces FDA Acceptance Of Investigational New Drug Application For AEB1102 9/14/2015 12:38:41 PM
Aeglea Appoints Sandy Mahatme And Russell Cox To Board Of Directors 7/8/2015 10:47:12 AM
Austin Firm Aeglea Files for $86 Million IPO 6/18/2015 6:27:32 AM
Eli Lilly (LLY),Novartis AG (NVS)-Backed Startup, Aeglea, Nabs $44 Million 3/23/2015 6:32:01 AM